nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Budget impact analysis of a personalized HBeAg negative CHB antiviral therapy model
|
Iannazzo, S. |
|
2013 |
45 |
S6 |
p. e369- 1 p. |
artikel |
2 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
|
Petta, S. |
|
2013 |
45 |
S6 |
p. e371- 1 p. |
artikel |
3 |
Identification and consumption of hepatopathic patients in Tuscany Region: Limits and opportunities of administrative data
|
Vainieri, M. |
|
2013 |
45 |
S6 |
p. e369-e370 nvt p. |
artikel |
4 |
Identification of responders to sorafenib in hepatocellular carcinoma: Is tumour volume measurement the way forward?
|
Sacco, R. |
|
2013 |
45 |
S6 |
p. e370- 1 p. |
artikel |
5 |
Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection
|
Maggio, R. |
|
2013 |
45 |
S6 |
p. e367-e368 nvt p. |
artikel |
6 |
Operational study on HBV/HCV in migrants in the Calabria Region (North Africa Emergency Program): Prevalence, HBsAg chronic carriers and outcomes
|
Surace, L.A. |
|
2013 |
45 |
S6 |
p. e368- 1 p. |
artikel |
7 |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
|
Petta, S. |
|
2013 |
45 |
S6 |
p. e370- 1 p. |
artikel |
8 |
Personalized sorafenib therapy for hepatocellular carcinoma
|
Cabibbo, G. |
|
2013 |
45 |
S6 |
p. e371- 1 p. |
artikel |
9 |
Protective effect of the Y220C mutant p53 during steatosis: Good news?
|
Gori, M. |
|
2013 |
45 |
S6 |
p. e368-e369 nvt p. |
artikel |
10 |
P53 status influences copper homeostasis in experimental model of hepatic steatosis
|
Arciello, M. |
|
2013 |
45 |
S6 |
p. e368- 1 p. |
artikel |
11 |
Rs4374383 single nucleotide polymorphism of MERTK gene influences the development of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis
|
Di Marco, V. |
|
2013 |
45 |
S6 |
p. e367- 1 p. |
artikel |